

New Clinical Trial for Bladder Cancer

Clinical trial for new treatment technology!

If your dog has been diagnosed with Bladder Transitional Cell Carcinoma/Urothelial Cell Carcinoma (bladder cancer), they may be a candidate for a new clinical trial!

Why a new trial?

Long-term outcome in dogs with bladder cancer is generally poor. Current treatment options can improve the patient's quality of life and lifespan, but remissions are rare and possible side-effects from intravenous chemotherapy are numerous (vomiting, diarrhea, decreased blood cell counts).

In this trial, we are testing a new way to deliver the chemotherapy:

- The treatment will be delivered directly into the bladder via a urinary catheter, so it can act directly at the tumor site.
- Additionally, before administration, the chemotherapeutic drug will be loaded into nanoparticles, which will bind specifically to the tumor and not to healthy bladder cells.

Those 2 technologies combined should allow a much more targeted delivery of the treatment, which should make it more effective, with hopefully fewer side effects.

What happens during the trial?

If you elect enrollment, this trial involves monthly visits at the Lloyd Veterinary Medical Center for 6 months for treatment administrations and tumor measurements.

If no improvement is detected after 2 months of treatment, your dog will be removed from the study and you will be offered standard of care treatment.

Will I have costs?

All treatment-related costs associated with the trial will be covered.



If you and your veterinarian think that your dog could be a candidate, please contact us!

Dr. Margaret Musser

Board-certified Oncologist

515-294-4900; mmusser@iastate.edu

Dr. Agnes Bourgois-Mochel

Clinical Trial Coordinator

515-291-9866, abmochel@iastate.edu